Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04602650 · ClinicalTrials.gov registry record

Microbial Determinants of Dementia Risk in Type 2 Diabetics of Mexican Descent

A clinical trial of Diabetes, sponsored by The University of Texas Medical Branch, Galveston.

Completed
Registry status
12
Enrollment target
1
Study location

NCT04602650: Completed study of Diabetes, sponsored by The University of Texas Medical Branch, Galveston.

NCT04602650 is a study of Diabetes that has completed, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 12 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04602650, a study of Diabetes, has completed, sponsored by The University of Texas Medical Branch, Galveston.

COMPLETED
Registry status
12 participants
Enrollment target
1
Study location

Study Summary

Type 2 diabetes (T2D) predisposes individuals to neurodegeneration and dementia, including Alzheimer's Disease (AD); yet the link between metabolic and neurodegenerative disorders remains unknown. Here, the investigators will study a well-defined human population with increased prevalence and early onset of both T2D and AD, individuals of Mexican descent living in South Texas. The study will begin to explore the possibility that disruption of the structure of the bacterial community residing in the gut in type 2 diabetic individuals of Mexican descent living in South Texas is directly related to the increased prevalence of early onset AD in this population. In this study, the investigators will perform gene sequencing on DNA isolated from fecal samples to identify and compare the populations of bacteria living in individuals with T2D versus non-diabetic controls. The investigators will analyze the findings to determine if the community structure of the gut microbiome of individuals of Mexican descent with T2D is significantly altered compared to that of non-diabetics within the same population. The investigators' findings could lead to the identification of early indicators of dementia onset as well as novel therapies for treating metabolic and neurodegenerative diseases.

Primary Outcome

Metagenomic 16S ribosomal RNA (rRNA) gene sequencing will be performed on subject samples to determine the presence and measure the relative abundance of operational taxonomic units representative of bacterial genera, species, and strains present in the fecal sample.

Conditions Studied

Study Locations (1)

Texas

  • University of Texas Medical Branch - Galveston

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2021-01-14
Est. Completion 2022-12-31

What the finished NCT04602650 record still lists

NCT04602650 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 0 interventions.

NCT04602650 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT04602650 about?

NCT04602650 is a clinical study titled "Microbial Determinants of Dementia Risk in Type 2 Diabetics of Mexican Descent". Type 2 diabetes (T2D) predisposes individuals to neurodegeneration and dementia, including Alzheimer's Disease (AD); yet the link between metabolic and neurodegenerative disorders remains unknown. Here, the investigators will study a well-defined human population with increased prevalence and early ...

What is the current status of trial NCT04602650?

This trial is currently completed. The enrollment target is 12 participants. The study started on 2021-01-14. Estimated completion is 2022-12-31.

What conditions does trial NCT04602650 study?

This clinical trial studies the following conditions: Diabetes.

Who is sponsoring clinical trial NCT04602650?

This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04602650 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04602650's enrollment target sits among peer trials

12 326th of 338 higher than 10 of 338 other Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04602650, the US trial registry maintained by the National Library of Medicine. NCT04602650 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.